Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Shares Sold by Stonepine Capital Management LLC

Stonepine Capital Management LLC decreased its position in Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Free Report) by 50.0% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 500,000 shares of the company's stock after selling 499,790 shares during the period. Milestone Pharmaceuticals accounts for about 1.0% of Stonepine Capital Management LLC's investment portfolio, making the stock its 27th biggest position. Stonepine Capital Management LLC owned approximately 0.94% of Milestone Pharmaceuticals worth $1,180,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of MIST. Jones Financial Companies Lllp boosted its holdings in shares of Milestone Pharmaceuticals by 1,000.0% in the fourth quarter. Jones Financial Companies Lllp now owns 11,000 shares of the company's stock valued at $26,000 after purchasing an additional 10,000 shares during the period. National Bank of Canada FI boosted its holdings in shares of Milestone Pharmaceuticals by 163.4% in the fourth quarter. National Bank of Canada FI now owns 18,700 shares of the company's stock valued at $44,000 after purchasing an additional 11,600 shares during the period. Cubist Systematic Strategies LLC purchased a new stake in shares of Milestone Pharmaceuticals in the fourth quarter valued at approximately $73,000. XTX Topco Ltd purchased a new stake in shares of Milestone Pharmaceuticals in the fourth quarter valued at approximately $80,000. Finally, Northern Trust Corp boosted its holdings in shares of Milestone Pharmaceuticals by 112.6% in the fourth quarter. Northern Trust Corp now owns 58,108 shares of the company's stock valued at $137,000 after purchasing an additional 30,772 shares during the period. Hedge funds and other institutional investors own 86.18% of the company's stock.

Analyst Ratings Changes

MIST has been the subject of a number of recent research reports. HC Wainwright reissued a "buy" rating and issued a $25.00 price objective on shares of Milestone Pharmaceuticals in a research note on Friday, March 28th. TD Securities lowered Milestone Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Tuesday, April 1st. TD Cowen lowered Milestone Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Tuesday, April 1st. Finally, Cowen lowered Milestone Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Tuesday, April 1st. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $17.00.

Milestone Pharmaceuticals Stock Down 0.7%

Milestone Pharmaceuticals stock traded down $0.01 during mid-day trading on Wednesday, reaching $1.38. 746,766 shares of the company were exchanged, compared to its average volume of 894,035. The business has a fifty day moving average of $1.24 and a 200 day moving average of $1.71. The firm has a market cap of $73.78 million, a P/E ratio of -1.70 and a beta of 0.86. The company has a debt-to-equity ratio of 2.18, a quick ratio of 15.40 and a current ratio of 15.40. Milestone Pharmaceuticals Inc. has a 12-month low of $0.63 and a 12-month high of $2.75.

Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.12). Research analysts anticipate that Milestone Pharmaceuticals Inc. will post -0.62 earnings per share for the current fiscal year.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.